Poor
Mostly Aligned
Patient Risk:
Moderate
Summary
Several fundamental mechanistic and administration route claims are consistent with the label, but multiple other claims (e.g., broader approval/regulatory dependence, “new amyloid” and “related organ damage” intent, and general prevalence statements about labs/injection-site reactions) are not supported by the provided prescribing information and are therefore unreliable.
Category Scores
Accurate Statements
Eplontersen is an antisense oligonucleotide.
12.1 Mechanism of Action: “Eplontersen is an antisense oligonucleotide-GalNAc conjugate…”
Eplontersen uses an antisense approach.
12.1 Mechanism of Action: degradation of TTR mRNA via antisense oligonucleotide mechanism.
Eplontersen targets the genetic message used by the body to make TTR.
12.1 Mechanism of Action: degradation of mutant and wild-type TTR mRNA.
Eplontersen reduces the amount of TTR protein circulating in the blood.
12.2 Pharmacodynamics: “decrease in serum TTR levels was observed.”
Eplontersen is administered as an injection.
3 Dosage Forms and Strengths: “Injection: 45 mg/0.8 mL…”
Eplontersen is given under the skin.
2.1 Recommended Dosage / 2.2 General Administration: “subcutaneous injection.”
In studies of TTR-amyloidosis antisense therapies, liver-related lab changes are common topics to watch.
5.1 and 12.2: WAINUA decreases serum vitamin A levels; discussed as a warning/precaution.
Eplontersen is studied for transthyretin amyloidosis, including forms that affect nerves.
1 Indications and Usage: “polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.”; 14 Clinical Studies: polyneuropathy due to hATTR amyloidosis.
Unsupported Statements
Eplontersen is a medicine being developed to treat transthyretin (TTR) amyloidosis.
The label provided describes an FDA-indicated product (WAINUA) rather than a development-stage therapy; the specific “being developed” framing is not supported.
Transthyretin amyloidosis involves misfolded TTR protein building up as amyloid deposits in the body.
The provided label excerpts do not explicitly state this mechanistic description; it is not directly supported by the included label text.
Eplontersen is designed to lower levels of TTR protein by blocking production of TTR in the liver.
Label excerpts support degradation of TTR mRNA and reduction of serum TTR, but do not state “blocking production of TTR in the liver.”
Lowering TTR is intended to reduce new amyloid formation.
No “intended to reduce new amyloid formation” statement appears in the provided label excerpts.
Lowering TTR is intended to reduce related organ damage.
No “intended to reduce related organ damage” statement appears in the provided label excerpts.
Eplontersen is studied for hereditary ATTR with polyneuropathy.
The label supports hereditary transthyretin-mediated amyloidosis with polyneuropathy in adults, but the claim wording omits “mediation” and is framed as “studied” rather than the actual approved indication; not cleanly supported as written.
The exact approved use of eplontersen depends on regulatory decisions in each country.
The provided label excerpts do not discuss cross-country regulatory variability.
In studies of TTR-amyloidosis antisense therapies, injection-site reactions are common topics to watch.
The provided label excerpts do not mention injection-site reactions or their frequency as a “common” topic.
Contradictions
Important Omissions
Recommended dosing frequency and dose (45 mg once monthly) and administration site details (upper thigh/abdomen; back upper arm only if healthcare provider/caregiver administers).
Importance:
Moderate
Vitamin A reduction and recommended vitamin A supplementation (warning/precaution), which is material to safety.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some claims are inconsistent with the provided labeling (e.g., “blocking production…in the liver,” “new amyloid formation/organ damage” intent, and unspecified “common” injection-site reaction topic). While the core administration route and general mechanism for lowering serum TTR are supported, unsupported/overgeneralized safety-related assertions may lead to misinterpretation of expected adverse effects and mechanism.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several mechanistic intent and safety-frequency/generalization claims are not supported by the provided label excerpts.
Suggested Improvement
Limit mechanism statements to the label-supported antisense degradation of TTR mRNA and reduction of serum TTR; avoid claims about liver-specific production blocking, “new amyloid formation,” “organ damage” intent, country-specific approval variability, and “common” injection-site reactions unless explicitly present in the provided prescribing information.